Table 2. Summary of CTCL patients’... | American Society of Hematology

Table 2.

Summary of CTCL patients’ peripheral blood flow cytometric parameters

Patient ID	Sorted abnormal cell population	Vβ gene identified	PCR of TCR	CD4:CD8 ratio	CD4⁺CD7^–, %	CD4⁺CD26^–, %	B stage
1	CD3^–CD4^–CD8^var+CD7^dim/–CD26^var+	ND	+	1.99	4.3	6.3	B2
2	CD3^dim+CD4⁺CD7^–CD26^–	ND	−	15.9	44.4	43.6	B1
3	CD3^dim+CD4^dim+CD7^dim+CD26^–	ND	+	2.11	1.6	21.9	B1
4	CD3⁺CD4⁺CD7⁺CD26^–	20, 8	+	31.1	17	69.7	B2
5	CD3^dim+CD4⁺CD7^–CD26^–	ND	+	10.08	47.4	76.5	B2
6	CD3⁺CD4⁺CD7^–CD26^–	ND	+	8.36	64.4	66.3	B1
7	CD3^dim+CD4^dim+CD7^–CD26^–	ND	+	7.14	27.3	38.5	B1
8	CD3⁺CD4⁺CD7^–CD26^+/−	13.6	+	3.18	9.3	11.6	B2
9	CD3^dim+CD4⁺CD7⁺CD26^–	17	+	6.06	3.8	49.7	B1
10	CD3⁺CD4⁺CD7⁺CD26^–	1	+	6.48	18.3	60.1	B2
11	CD3^dim+CD4⁺CD7^–CD26^–	13.2	+/−	2.61	31.5	33.6	B1
12	CD3^dim+CD4⁺CD7⁺CD26^–	ND	+	36.86	12.7	70.4	B2
13	CD3^dim+CD4⁺CD26^-CD7^–	12	+	57.4	71	80.3	B2
14	CD3⁺CD4⁺CD7^–CD26^–	ND	−	5.32	71.6	79.5	B2
15	CD3⁺CD4⁺CD7^–CD26^–	ND	−	1.53	31.9	37.2	B2
16	CD3⁺CD4⁺CD7⁺CD26^–	ND	−	23.82	76.4	85.8	B2
17	CD3⁺CD4⁺CD7^dim/–CD26^–	22	+	2.76	24.7	36.1	B2
18	CD3⁺CD4⁺CD7^–CD26^dim/–	27	−	18.71	65.2	58.4	B1
19	CD3^dim+CD4^dim+CD7^–CD26^–	13.1	+	22.3	9.8	63.4	B2

Patient ID	Sorted abnormal cell population	Vβ gene identified	PCR of TCR	CD4:CD8 ratio	CD4⁺CD7^–, %	CD4⁺CD26^–, %	B stage
1	CD3^–CD4^–CD8^var+CD7^dim/–CD26^var+	ND	+	1.99	4.3	6.3	B2
2	CD3^dim+CD4⁺CD7^–CD26^–	ND	−	15.9	44.4	43.6	B1
3	CD3^dim+CD4^dim+CD7^dim+CD26^–	ND	+	2.11	1.6	21.9	B1
4	CD3⁺CD4⁺CD7⁺CD26^–	20, 8	+	31.1	17	69.7	B2
5	CD3^dim+CD4⁺CD7^–CD26^–	ND	+	10.08	47.4	76.5	B2
6	CD3⁺CD4⁺CD7^–CD26^–	ND	+	8.36	64.4	66.3	B1
7	CD3^dim+CD4^dim+CD7^–CD26^–	ND	+	7.14	27.3	38.5	B1
8	CD3⁺CD4⁺CD7^–CD26^+/−	13.6	+	3.18	9.3	11.6	B2
9	CD3^dim+CD4⁺CD7⁺CD26^–	17	+	6.06	3.8	49.7	B1
10	CD3⁺CD4⁺CD7⁺CD26^–	1	+	6.48	18.3	60.1	B2
11	CD3^dim+CD4⁺CD7^–CD26^–	13.2	+/−	2.61	31.5	33.6	B1
12	CD3^dim+CD4⁺CD7⁺CD26^–	ND	+	36.86	12.7	70.4	B2
13	CD3^dim+CD4⁺CD26^-CD7^–	12	+	57.4	71	80.3	B2
14	CD3⁺CD4⁺CD7^–CD26^–	ND	−	5.32	71.6	79.5	B2
15	CD3⁺CD4⁺CD7^–CD26^–	ND	−	1.53	31.9	37.2	B2
16	CD3⁺CD4⁺CD7⁺CD26^–	ND	−	23.82	76.4	85.8	B2
17	CD3⁺CD4⁺CD7^dim/–CD26^–	22	+	2.76	24.7	36.1	B2
18	CD3⁺CD4⁺CD7^–CD26^dim/–	27	−	18.71	65.2	58.4	B1
19	CD3^dim+CD4^dim+CD7^–CD26^–	13.1	+	22.3	9.8	63.4	B2

Abnormal cell phenotype identified by flow cytometry as phenotypically atypical: TCR-Vβ⁺ if >50% of the population of atypical cells express a single Vβ, or by indirect evidence, if there is <20% expression of the entire 27 Vβ antibody panel. Polymerase chain reaction positive (PCR⁺) if ≥1 of 3 PCRs identifies a clone. B stage based on International Society for Cutaneous Lymphomas classification and the 2016 criteria proposed by Gibson et al.²³ Patients staged as B2 have elevated absolute CD3⁺ or CD3⁺CD4⁺ cell counts, with the upper limits of normal defined as >2245 cells/μL and >1612 cells/μL, respectively. CD4⁺CD7^– and CD4⁺CD26^– percent specifications are defined as percentage of peripheral blood mononuclear cells (lymphocytes and monocytes). ID, identifier; ND, not distinguished.

View Large

This Feature Is Available To Subscribers Only